Additional baseline clinical and demographic information is presented in Table 3, which displays baseline characteristics of participants in TRAILBLAZER‐ALZ 3 alongside baseline data from the cognitively unimpaired, amyloid‐negative population of the LEARN study,13 the preclinical AD population enrolled in the A4 study,10 and participants with low/medium tau enrolled in TRAILBLAZER‐ALZ 2 with a baseline CDR‐GS of 0.5. Here, MAPT is linked to Alzheimer disease.